Owens & Minor in the news
Healthcare solutions provider
Tamtam found 20 recent articles about Owens & Minor.
- Owens & Minor (NYSE:OMI) Lowered to Strong Sell Rating by Zacks Research
Owens & Minor's stock has been downgraded to strong sell amid earnings misses and lowered price targets, despite insider buying and mixed analyst opinions.
- Owens & Minor Faces Dual Challenge After Index Removal
Owens & Minor faces market and financial challenges as it restructures to focus on Patient Direct services after a failed acquisition and index removal.
- Owens & Minor Bets On Home Care After Tough Year
Owens & Minor is pivoting to home care by selling its hospital supply segment amid financial struggles and market skepticism.
- OMI - Rising Healthcare Pressures Will Exacerbate Patient Direct Vulnerabilities
Owens & Minor's shift to a narrower Patient Direct segment amid rising competition, cost pressures, and high debt creates revenue and margin challenges, though strategic moves target improved profitability.
- Owens & Minor Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
Schall Law Firm is investigating Owens & Minor for possible securities violations following the CFO's resignation and subsequent stock price drop.
- UBS Reduces PT on Owens & Minor, Inc. (OMI) from $13 to $7 Following Weaker Q2 2025 Results
UBS cut Owens & Minor's price target to $7 after disappointing Q2 2025 results.
- Day 5 of Loss Streak for Owens & Minor Stock with -11% Return (vs. -61% YTD) [8/22/2025]
Owens & Minor's stock has fallen 11% over five days, contributing to a 61% decline year-to-date.
- Owens & Minor Stock (OMI) Opinions on Q2 2025 Earnings Miss
Owens & Minor's Q2 2025 earnings miss caused a sharp stock decline amid strategic divestment and mixed investor sentiment.
- Owens & Minor, Inc. shares rise 2.75% premarket after being mentioned as a prominent player in the traditional wound care market.
Owens & Minor shares rose premarket as the company is highlighted as a key player in the evolving wound care market.
- Coliseum capital buys Owens & Minor (OMI) shares worth $8.1 million
Coliseum Capital increased its stake in Owens & Minor amid mixed Q2 2025 earnings and a lowered UBS price target.
- Owens & Minor refocuses on Patient Direct
Owens & Minor is focusing on debt reduction and strengthening its Patient Direct business amid mixed diabetes supply sales and limited Medicare competitive bidding exposure.
- Analysts' 4 Projections for Owens & Minor: Bullish to Bearish Sentiments
Analysts show mixed views on Owens & Minor with lowered price targets amid a slight earnings miss, while institutional investors increase stakes.
- Owens & Minor, Inc. (NYSE:OMI) Q2 2025 Earnings Call Transcript
Owens & Minor is divesting its Products & Healthcare Services segment to focus on growing its Patient Direct home-based care business, projecting strong 2025 revenue and EBITDA despite near-term divestiture costs.
- UBS Maintains Owens & Minor(OMI.US) With Buy Rating, Cuts Target Price to $7
UBS keeps a buy rating on Owens & Minor but cuts the target price from $13 to $7.
- Owens & Minor Second Quarter 2025 Earnings: Misses Expectations
Owens & Minor's Q2 2025 earnings showed a significant revenue drop and widened losses, missing analyst expectations and leading to a 16% share price decline.
- Lexington Events - Owens & Minor 30th Annual United Way Golf Tournament
Owens & Minor's 30th Annual United Way Golf Tournament in Lexington faces rainy weather with 1-2 inches of rain expected.
- Owens & Minor Inc (OMI) Q2 2025 Earnings Call Highlights: Navigating Growth Amid Challenges
Owens & Minor discussed its Q2 2025 earnings, emphasizing growth amid market challenges.
- UBS Adjusts Price Target on Owens & Minor to $7 From $13, Maintains Buy Rating
UBS cut Owens & Minor's price target to $7 but kept a Buy rating, while analysts average a Hold rating with a $7.28 target.
- UBS lowers Owens & Minor stock price target to $7 on disappointing outlook
UBS cut Owens & Minor's stock target to $7 citing weak Q2 results and outlook, but notes potential recovery opportunities and expects profitability in 2025.
- Owens & Minor’s Asset Sale: Potential Risks and Financial Implications
Owens & Minor's planned asset sale in its P&HS segment carries risks of retained liabilities, financial strain, and potential earnings dilution.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Owens & Minor?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies